On December 27, 2024, the official website of the Beijing Stock Exchange announced that Dynamiker Biotechnology (Tianjin) Co., Ltd. has received approval for its initial public offering (IPO) from the listing committee, with Citic Securities serving as the sponsor. The company aims to raise RMB 456 million (approximately USD 64 million) through this offering.<\/p>\n\n\n\n
Core Business and Product Offerings<\/strong> Innovative Diagnostic Solutions<\/strong>
According to the prospectus, Dynamiker Biotechnology specializes in the early diagnosis of invasive fungal diseases and the development, production, and sale of in vitro diagnostic products for various pathogens. The company has been recognized as a national high-tech enterprise and is among the first batch of key specialized and innovative “little giant” enterprises supported by the government. It has also been awarded the title of a champion enterprise in Tianjin’s manufacturing sector and recognized as a national intellectual property advantage enterprise.<\/p>\n\n\n\n
Dynamiker’s primary product includes the (1-3)-\u03b2-D-glucan detection kit (colorimetric method) and other enzyme kinetics series reagents, utilizing horseshoe crab blood cells as a core raw material. The company holds a license for the operation and utilization of horseshoe crab blood and its products, allowing for the legal use of existing horseshoe crab blood cells. Since 2020, Dynamiker has not engaged in the procurement or blood collection of horseshoe crabs, relying instead on its stock of raw materials, which is sufficient to meet production needs for over five years.<\/p>\n\n\n\n